XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 37,647 $ 38,620
Operating expenses    
Cost of revenue 18,681 13,192
Research and development 32,601 37,839
Sales and marketing 22,308 26,093
General and administrative 20,831 24,144
Amortization of intangible assets 419 419
Total operating expenses 94,840 101,687
Loss from operations (57,193) (63,067)
Interest and other income, net 3,024 271
Interest expense (3,531)  
Net loss (57,700) (62,796)
Add: Net loss attributable to noncontrolling interest 1 60
Net loss attributable to Adaptive Biotechnologies Corporation $ (57,699) $ (62,736)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.40) $ (0.44)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 143,511,142 141,697,252
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.40) $ (0.44)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 143,511,142 141,697,252